Evidence map›Paper›PMID 38223561›Full record

ArticleInfection and drug resistance2024

Omadacycline for the Treatment of Severe

Juan Wang, Shuangyong Dong, Mengjuan Fang, Zhiyan Fan, Yuansheng Xu

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection and drug resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Observational
  2. Clinical management and pharmaceutical care of severeFrontiers in cellular and infection microbiology · 2026
    Review
  3. Article
  4. Effectiveness of Omadacycline in a Patient withInfection and drug resistance · 2025
    Article
  5. Case Report of SevereInternational medical case reports journal · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Juan WangDepartment of Emergency, Affiliated Hangzhou First People`s Hospital, School of Medicine, Westlake University, Hangzhou, People's Republic of China.ORCID 0000-0003-0044-2813
Shuangyong DongDepartment of Emergency, Affiliated Hangzhou First People`s Hospital, School of Medicine, Westlake University, Hangzhou, People's Republic of China.
Mengjuan FangDepartment of Emergency, Affiliated Hangzhou First People`s Hospital, School of Medicine, Westlake University, Hangzhou, People's Republic of China.ORCID 0009-0008-2258-0719
Zhiyan FanDepartment of Emergency, Affiliated Hangzhou First People`s Hospital, School of Medicine, Westlake University, Hangzhou, People's Republic of China.
Yuansheng XuDepartment of Emergency, Affiliated Hangzhou First People`s Hospital, School of Medicine, Westlake University, Hangzhou, People's Republic of China.ORCID 0000-0002-5350-8401
Westlake University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Case Presentation: A 77-year-old female patient was admitted to the hospital presenting with symptoms of fever, low back pain, and headache. The diagnosis of Conclusion: This case provides evidence supporting the potential use of omadacycline as a therapeutic option for the treatment of severe

Indexed as

Chlamydia psittaci pneumoniaGuillain-Barre syndromemetagenomic next‑generation sequencingomadacycline

Identifiers

PMID38223561
PMCPMC10787558
OpenAlexW4390685236

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.